What's New: July 2026 Update TRIUMPH-4 confirmed as final: 28.7% weight loss at 68 weeks in 445 participants peer-reviewed Phase 3 data, December 2025 TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients the pivotal general obesity trial met all primary and key secondary endpoints TRIUMPH-1 extension: In a prespecified 104-week extension, patients reached 30.3% average weight loss weight loss does not plateau at 80 weeks TRANSCEND-T2D-1 CONFIRMED (topline March 2026, published June 2026): First dedicated Phase 3 diabetes trial -2.0% HbA1c and 16.8% weight loss in 537 type 2 diabetes patients, separate from the TRIUMPH obesity program OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour TRIUMPH-2 (obesity + diabetes) and TRIUMPH-3 (obesity + cardiovascular disease) results expected later in 2026 Introduction Retatrutide's clinical journey tells a story of escalating and now confirmed efficacy
Its important to remember that libido changes are normalbut still worth exploring
Use sunscreen in the morning to prevent dullness and pigmentation
Skin feels firmer with improved elasticity
Thats where the right supplements come in
Sun exposure While the area is healing from any minimal swelling or bruising, avoid any sun exposure or sun beds for up to a week after the treatment
